Back to Multiple Sclerosis
NCT04676204
NCT04676204
Who may be able to join
Who might be able to join this trial:
- You are 18 years old or older.
- You have been officially diagnosed with multiple sclerosis.
- You have recently started (either as a new prescription or by switching) one of these six specific MS medications within the last 2 months: cladribine, dimethyl fumarate, fingolimod, teriflunomide, ozanimod, or diroximel fumarate.
- You are able to read and write in English.
- You have access to the internet and a computer to complete the study assessments.
Who may not be able to join:
- You are currently taking an MS medication other than the six listed above (cladribine, dimethyl fumarate, fingolimod, teriflunomide, ozanimod, or diroximel fumarate).
- You have another neurological condition alongside your multiple sclerosis.
- You have significant cognitive (thinking or memory) or psychological difficulties that your MS care team (such as your neurologist or MS nurse) believes would make it too difficult for you to take part in the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Status
By Invitation
Phase
Not Applicable
Sponsor
Monash University
Registry
clinicaltrials_gov
Start date
25 September 2020
Est. completion
19 November 2025
Where this trial is recruiting
🇦🇺 Australia
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Medication Burden; Medication Adherence (MPR); Medication Adherence (PDC)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.